EGFR Monoclonal Antibody for Advanced Gastric Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate efficacy and safety of EGFR monoclonal antibody
(Cetuximab/Nimotuzumab) in combination with a chemotherapy in gastric cancer patients with
EGFR amplification.